Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (10,5 Mio. €): Optimale Behandlung von Patienten mit soliden Tumoren in Europa durch Künstliche Intelligenz Hor01.10.2021 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Optimale Behandlung von Patienten mit soliden Tumoren in Europa durch Künstliche Intelligenz
OPTIMA is a multi-stakeholder-led consortium with the vision that each and every patient should have access to the most up-to-date individualised treatments and to innovative therapies. In that perspective, we will design, develop and deliver the first interoperable and GDPR compliant European real-world oncology data and evidence generation platform, along with decision support toolsets for prostate, lung and breast cancer. By designing this platform from the onset based on the needs of the clinicians and patients in an inclusive and sustainable way, OPTIMA aims to strengthen shared decision-making based on innovative data and AI-driven technology and tools. To achieve our vision, we have united the key partners from other data-driven European wide oncology initiatives (PIONEER, EHDEN, HARMONY) in our project along with Europes leading clinicians in the fields of breast, prostate and lung cancer that all have leading roles in medical societies such as ERS, ESMO, and EAU. At the core of the OPTIMA project are the major guideline offices of the three indications, whilst the project is further strengthened by patient advocacy groups, well-known academic partners and 6 SMEs as partners covering the needed expertise to implement OPTIMA successfully. The platform will build on existing open source solutions such as the OMOP-CDM, tranSMART and OHDSI ATLAS whilst developing novel AI models based on federated learning to facilitate knowledge discovery. At the start of the project, we will already have access to datasets covering over 200M people in Europe, along with data from high quality patient cohorts for AI model building. Moreover, the platform will be hosted in-kind on existing infrastructure provided by Helmholtz Institute in Germany. Finally, OPTIMA envisions sustainability of its platform through a value-based approach with various business models for commercial users.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| ARTTIC INNOVATION GmbH | 130.693 € |
| Abbvie Inc. | 0,00 € |
| Amgen | 0,00 € |
| Association Eisbm | 884.000 € |
| Astrazeneca AB | 0,00 € |
| BAYER AG | 0,00 € |
| DEUTSCHE KREBSGESELLSCHAFT e. V. | 99.993 € |
| EUROPEAN RESPIRATORY SOCIETY | 126.750 € |
| Erasmus Universitair Medisch Centrum Rotterdam | 561.257 € |
| European Cancer Patient Coalition | 75.000 € |
| European Lung Foundation | 127.312 € |
| European Organisation for Research AND Treatment OF Cancer Aisbl | 75.001 € |
| F. HOFFMANN-LA ROCHE AG | 0,00 € |
| 200.416 € | |
| 744.353 € | |
| HELIOS KLINIKUM EMIL VON BEHRING GmbH | 0,00 € |
| HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF e. V. | 684.000 € |
| Information Technology FOR Translational Medicine (Ittm) SA | 787.500 € |
| Institut de Cancerologie de l'Ouest | 90.000 € |
| Istituto Europeo DI Oncologia Srl | 50.000 € |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | 40.000 € |
| Lunds Universitet | 71.000 € |
| Lungs Europe | 0,00 € |
| MUTABOR TECHNOLOGIES GmbH | 0,00 € |
| Owkin France | 299.962 € |
| Pfizer Ltd. | 0,00 € |
| Queen Mary University of London | 220.000 € |
| Region Uppsala | 483.000 € |
| SMART REPORTING GmbH | 398.250 € |
| Stichting European Urological Foundation | 822.280 € |
| 470.000 € | |
| The Chancellor, Masters and Scholars of the University of Oxford | 967.594 € |
| 613.424 € | |
| 326.218 € | |
| Universita Vita-Salute SAN Raffaele | 50.125 € |
| Universitat Wien | 433.130 € |
| Universiteit Maastricht | 300.000 € |
| University College London | 98.590 € |
| Uppsala Universitet | 67.875 € |
| 162.275 € |
Quelle: https://cordis.europa.eu/project/id/101034347
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "ARTTIC INNOVATION GmbH - EU-Förderung (10,5 Mio. €): Optimale Behandlung von Patienten mit soliden Tumoren in Europa durch Künstliche Intelligenz"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
